NovelBeam Technology Names CFO; Shares Slump 11%
Haitai Xinguang (688677): The light of domestic endoscopes, waiting quietly for the recovery of overseas orders.
Investment Highlights: The company is the sole supplier of fluorescent endoscopes for Stryker Corp: HaiTaiXinGuang was established in 2003, mainly engaged in the research and development, production, and sales of medical endoscopes as well as optical products. The company is committed to exploring the integration of optical technology with medicine, industry, and
Haitai Xinguang (688677.SH): Since July of this year, it has been accepting endoscope orders from customers in the USA.
On September 19, Gelonghui stated on the investor interaction platform that Haitai Xinguang (688677.SH) has indicated that its Nevada subsidiary in the USA has been certified by American clients. It has been accepting endoscope orders from American clients since July this year. The progress of overseas business is proceeding as usual.
Express News | Haitai Xinguang: Ms. Zheng Jinlan was elected as the employee representative supervisor of the fourth session of the Board of Supervisors.
Express News | Star market closing review: SSE Science and Technology Innovation Board 50 Index fell 0.40%, semiconductor sector showed mixed gains and losses.
Haitai Xinguang (688677.SH): Cumulative repurchase of 0.6110% of the company's shares
On September 2, Guolonghui announced that as of August 31, 2024, Qingdao Haitai Xinguang Technology Co., Ltd. repurchased 737,000 shares of the company's stock through the Shanghai Stock Exchange trading system through centralized bidding trading, accounting for 0.6110% of the company's total share capital of 120,614,000 shares. The highest price of the repurchase transaction was 40.75 yuan per share, and the lowest price was 28.89 yuan per share. The total amount paid was RMB 26,109,622.58 (excluding stamp duty, trading commissions, and other transaction costs).
Haitai Xinguang (688677) 2024 Interim Report Review: Temporary performance pressure caused by customer inventory reduction, with high growth in overall sales revenue.
Company released its 2024 interim report, with a revenue of 0.22 billion yuan (-17.70%) and a net income attributable to the parent company of 0.071 billion yuan (-21.02%), and a non-GAAP net income of 0.065 billion yuan (-24.55%). 2
Express News | 158 companies received institutional research.
Express News | 121 companies received institutional research
Express News | 115 companies were surveyed by institutions, with Hangzhou Hikvision Digital Technology being the most popular.
Express News | 101 companies have been surveyed by institutions.
Express News | Star market closing review: medical instrument sector led the decline, while semiconductor and software sectors performed poorly throughout the day.
Express News | The social security fund holds 15 Star Market stocks: 5 new stocks and 2 shareholding stocks.
Haitai Xinguang (688677): The purchasing pace of major customers slows down, waiting for the level of shipments to recover.
Event: The company released its 2024 semi-annual report, achieving a revenue of 0.22 billion yuan (-17.7% YoY), a net income attributable to shareholders of 0.071 billion yuan (-21.0% YoY), and a non-GAAP net income attributable to shareholders of 0.065 billion yuan.
Haitai Xinguang (688677): Performance is impacted by customer inventory reduction, orders are expected to recover in the second half of the year.
Event: The company released its 2024 semi-annual report, achieving revenue of 0.22 billion yuan in H1 2024, a 17.70% year-on-year decrease, with a net income of 0.071 billion yuan attributable to shareholders, a 21.02% year-on-year decrease, excluding non-recurring gains and losses.
Express News | Heavyweight stocks in the social security fund surfaced, with 26 companies holding for more than two years.
Haitai Xinguang (688677): Q2 revenue decline, long-term growth certainty remains.
Investment highlights: The company has released its 2024 interim report, with revenue of 0.22 billion yuan in H1 2024, a YoY decrease of 17.7%; net income attributable to the parent company is 0.071 billion yuan, a YoY decrease of 21.02%. Among them, Q2 revenue was 1.03.
Haitai New Light (688677): The performance of pharmaceuticals/necessary consumer goods is under pressure due to inventory, and is expected to improve in the second half of the year.
Report Overview: Sales slowed down due to the impact of US customers reducing inventory. In the second half of the year, with the mass production of endoscopes and further increase in overall sales volume, performance is expected to improve, maintaining a shareholding recommendation. Investment points: Maintaining a shareholding recommendation. The company achieved revenue in the first half of 2024.
Summary of Hite New Light's 2024 interim report.
Haitai Xinguang 2024 Semi-Annual Report
No Data
No Data